Home - Products - Angiogenesis - EGFR - Lidocaine Hydrochloride hydrate

Lidocaine Hydrochloride hydrate

CAS No. 6108-05-0

Lidocaine Hydrochloride hydrate ( —— )

Catalog No. M15297 CAS No. 6108-05-0

Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 49 In Stock
100MG 63 In Stock
200MG 88 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Lidocaine Hydrochloride hydrate
  • Note
    Research use only, not for human use.
  • Brief Description
    Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo.
  • Description
    Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR; Sodium Channel
  • Research Area
    Cardiovascular Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    6108-05-0
  • Formula Weight
    288.82
  • Molecular Formula
    C14H22N2O·HCl·H2O
  • Purity
    >98%(HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    O.Cl.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Sheets PL, et al. J Physiol. 2007 Jun 15;581(Pt 3):1019-3
molnova catalog
related products
  • (Rac)-JBJ-04-125-02

    JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.

  • AG 99

    AG-99 is an inhibitor of EGFR kinase (IC50: 10 μM in the human epidermoid carcinoma cell line A431).

  • AG-1478

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.